Document Detail


Severe cytokine release syndrome after the first dose of Brentuximab vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
MedLine Citation:
PMID:  24913471     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Brentuximab vedotin is an antibody-drug conjugate targeting CD30. We report a case of severe cytokine release syndrome (CRS) after administration of the first dose of Brentuximab vedotin in a 64-year old patient with relapsed systemic anaplastic large cell lymphoma (sALCL). To our knowledge, this is the first case of CRS to Brentuximab vedotin described in the literature. However, CRS to Brentuximab vedotin might be underestimated, as the drug has not been tested in large phase III trials yet. This article is protected by copyright. All rights reserved.
Authors:
Stefan K Alig; Martin Dreyling; Bettina Seppi; Benedikt Aulinger; Lukas Witkowski; Christina Rieger
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-6-10
Journal Detail:
Title:  European journal of haematology     Volume:  -     ISSN:  1600-0609     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-6-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
This article is protected by copyright. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predicting dosing advantages of factor VIIa variants with altered tissue factor and lipid-dependent ...
Next Document:  Road safety and simulation conferences: An interdisciplinary network for safer roads.